|Table of Contents|

The expression and clinical significance of BMPER in serous ovarian tumors

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 05
Page:
855-859
Research Field:
Publishing date:

Info

Title:
The expression and clinical significance of BMPER in serous ovarian tumors
Author(s):
XI Yong1; 2; WANG Jing1; LI Xiao1; NIE Xin1; GAO Lingling1; JIN Shan3; GUO Qian1; WANG Caixia1; LIU Juanjuan1; LIN Bei1
1.Department of Obstetrics and Gynecology,Shengjing Hospital Affiliated to China Medical University,Liaoning Shenyang 110004,China;2.Dalian Municipal Maternal and Child Health Care Hospital,Liaoning Dalian 116033,China; 3.Liaoning Cancer Hospital,Liaoning Shenyang 110042,China.
Keywords:
BMPER; ovarian cancer; immunohistochemistry
PACS:
R737.31
DOI:
DOI:10.3969/j.issn.1672-4992.2021.05.030
Abstract:
Objective:To detect the expression of BMPER in ovarian serous tumor tissue samples and to analyze its relationship with the clinicopathological parameters and the prognosis of ovarian serous carcinoma.Methods:BMPER expression in 59 ovarian serous carcinoma,21 ovarian serous borderline tumor,23 ovarian serous benign tumor and 28 normal ovarian tissue samples were detected by immunohistochemistry.Its relationship with the clinicopathological parameters and the prognosis was analyzed.Results:BMPER was predominantly expressed in the cytoplasm and intercellular space.The positive rate of BMPER expression in the ovarian serous carcinoma (89.83%) samples was substantially higher than those in the ovarian borderline tumor (76.19%),ovarian benign tumor (39.13%) and normal ovarian tissue (28.57%) samples,and there was significant difference compared with the latter two groups (P<0.01).The high expression rate of BMPER in the positive lymph node metastasis group and the advanced ovarian cancer group was higher than that in the negative lymph node metastasis group and early stage group (P<0.05).Kaplan-Meier (KM) survival analysis showed that the survival rate of patients with BMPER high expression was significantly lower than that of patients in the low expression group.Cox regression analysis showed that BMPER high expression was an independent risk factor of poor prognosis for patients (P=0.025).Conclusion:BMPER is highly expressed in ovarian serous cancer and is closely correlated to the poor prognosis of ovarian cancer.Therefore,BMPER is a potential prognostic marker for ovarian cancer.

References:

［1］LALREMMAWIA H, TIWARY,BASANT K.Identification of molecular biomarkers for ovarian C-ancer using computational approaches［J］.Carcinogenesis,2019,40(6):742-748.
[2]REID BM,PERMUTH JB,SELLERS TA.Epidemiology of ovarian cancer:A review［J］.Cancer Biology & Medicine,2017,14(1):9.
[3]HELLSTROM I,RAYCRAFT J,HAYDEN-LEDBETTER M,et al.The HE4 (WFDC2) protein is a bioma-rker for ovarian carcinoma［J］.Cancer Res,2003,63(13):3695-3700.
[4]ZHU L,ZHUANG H,WANG H,et al.Overexpression of HE4 (human epididym-is protein 4) enhances proliferation,invasion and metastasis of ovarian cancer［J］.Oncotarget,2016,7(1):729-744.
[5]MOSER M,BINDER O,WU Y,et al.BMPER,a novel endothelial cell precursor-derived prote in,antagonizes bone morphogenetic protein signaling and endothelial cell differentiation［J］.Mol Cell Biol,2003,23(16):5664-5679.
[6]GREENBAUM L,GILBOA Y,RAAS-ROTHSCHILD A,et al.Diaphanospondylodysostosis:Refining the prenatal diagnosis of a rare skeletal disorder［J］.Eur J Med Genet,2019,62(3):167-171.
[7]LOCKYER P,MAO H,FAN Q,et al.LRP1-Dependent BMPER signaling regulates lipopolys-accharide-induced vascular inflammation［J］.Arterioscler Thromb Vasc Biol,2017,37(8):1524-1535.
[8]BETHGE N,HONNE H,ANDRESEN K,et al.A gene panel,including LRP12,is frequently hype-rmethylated in major types of B-cell lymphoma［J］.PLoS One,2014,9(9):e104249.
[9]GRENIER JK,FOUREMAN PA,SLOMA EA,et al.RNA-seq transcriptome analysis of formalin fixed,paraffin-embedded canine meningioma［J］.PLoS One,2017,12(10):e187150.
[10]HEINKE J,KERBER M,RAHNER S,et al.Bone morphogenetic protein modulator BMPER is highly expressed in malignant tumors and controls invasive cell behavior［J］.Oncogene,2012,31(24):2919-2930.
[11]BEIRNE JP,MCART DG,RODDY A,et al.Defining the molecular evolution of extrauterine high grade serous carcinoma［J］.Gynecologic Oncology,2019,155(2):305-317.
[12]AHMED AA,ETEMADMOGHADAM D,TEMPLE J,et al.Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary［J］.Journal of Pathology,2010,221(1):49-56.
[13]BEIRNE JP,IRWIN GW,MCINTOSH SA,et al.The molecular and genetic basis of inheritedcancer risk in gynaecology［J］.Obstetrician & Gynaecologist,2015,17(4):233-241.
[14]HELBING T,WILTGEN G,HORNSTEIN A,et al.Bone morphogenetic protein-modulator BMPER regulates endothelial barrier function［J］.Inflammation,2017,40(2):442-453.
[15]LOCKHART-CAIRNS MP,LIM KTW,ZUK A,et al.Internal cleavage and synergy with twisted gastrulation enhance BMP inhibition by BMPER［J］.Matrix Biology,2019,77(4):73-86.
[16]JUMABAY M,ZHUMABAI J,MANSUROV N,et al.Combined effects of bone morphogenetic protein 10 and crossveinless-2 on cardiomyocyte differentiation in mouse adipocyte-derived stem cells［J］.Journal of Cellular Physiology,2018,233(3):1812-1822.
[17]DYER L,LOCKYER P,WU Y,et al.BMPER promotes epithelial-mesenchymal transition in the developing cardiac cushions［J］.PLoS One,2015,10(9):e0139209.
[18]XIAO F,WANG C,WANG C,et al.BMPER enhances bone formation by promoting the osteogenesis-angiogenesis coupling process in mesenchymal stem cells［J］.Cell Physiol Biochem,2018,45(5):1927-1939.
[19]WILLIS MS,DYER LA,REN R,et al.BMPER regulates cardiomyocyte size and vessel denssity in vivo［J］.Cardiovasc Pathol,2013,22(3):228-240.
[20]DONG Y,GENG Y,LI L,et al.Blocking follistatin-like 1 attenuates bleomycin-induced pulmonary fibrosis in mice［J］.J Exp Med,2015,212(2):235-252.
[21]HUAN C,YANG T,LIANG J,et al.Methylation-mediated BMPER expression in fibroblast activation in vitro and lung fibrosis in mice in vivo［J］.Sci Rep,2015,5:14910.

Memo

Memo:
National Natural Science Foundation of China(No.81672590）；国家自然科学基金（编号：81672590）；盛京自由研究者基金（编号：201303）
Last Update: 2021-01-29